The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Trend alert! Split dosing, stretch dosing, skip dosing, microdosing Ozempic… People are finding creative ways to use ...

In this weekly Plain Facts compilation, we present to you data-based insights, with easy-to-read charts, to help you delve deeper into the stories reported by Mint in the week gone by.

Despite being on the market for less than three years, GLP-1 medicines, Mounjaro and Zepbound, became key top-line drivers for Lilly, with demand rising rapidly.However, to maintain its prowess in the ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster treatment, an early-stage trial showed, as the drugmaker races to develop ...

Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.

As weight loss jabs grow in popularity, experts say people using Wegovy or Mounjaro see far better results when they build consistent tracking habits alongside doctor-led care.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what researchers found.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what researchers found.